• Total Issue Size – Up To 62,53,200 Equity Shares of ₹ 10 each
  • IPO Size – ₹ 214.48 Crore (At Upper Price Band)
  • Price Band – ₹ 326 – ₹ 343 Per Share
  • Lot Size – 400 Equity Shares

Mumbai : Q-Line Biotech Limited is an Indian in-vitro diagnostics (IVD) and healthcare solutions company engaged in manufacturing and supplying diagnostic reagents, rapid test kits, molecular diagnostics, pathology equipment and related consumables used by hospitals, laboratories and healthcare institutions across India. Proposes to open its Initial Public Offering on May 21, 2026, aiming to raise ₹ 214.48 Crores (at upper price band) with shares to be listed on the NSE Emerge platform.

The issue size is 62,53,200 equity shares with a face value of ₹ 10 each with a price band of ₹ 326 – ₹ 343 Per Share.

Equity Share Allocation

  • QIB Anchor Portion – Upto 17,81,200 Equity Shares
  • Net QIB – Upto 11,88,000 Equity Shares
  • Non-Institutional Investors – Not Less Than 8,91,600 Equity Shares
  • Individual Investors – Not Less Than 20,79,200 Equity Shares
  • Market Maker – 3,13,200 Equity Shares

The net proceeds from the IPO will be utilized for to meet working capital, requirements repayment of certain borrowing and the general corporate purposes. The anchor bidding is on Wednesday, May 20, 2026. The issue will open on Thursday, May 21, 2026 and will close on Monday, May 25, 2026.

The Book Running Lead Manager to the Issue is HEM Securities Limited & Share India Capital Services Private Limited, and the Registrar is Purva Sharegistry (India) Private Limited.